University of Connecticut Health Centre team is demonstrating new ways that MRI can be used as a superior way to detect and characterise small, rapidly-growing tumours
Researchers at the University of Connecticut Health Centre (UCHC) are exploring applications of Maple in the interpretation of magnetic resonance imaging (MRI) information for the early detection and characterisation of small tumours.
Vascular networks required for nurturing growth in tumour microenvironments can be much denser than in normal tissue. Vascular density is an important parameter in assessing tumour activity, but it is universally appreciated that accurate determination is a difficult task.
Determination of this parameter is based on manual counting procedures and is observer subjective.
At best, one has to be satisfied with relative measurements.
Moreover, these measurements are very labour intensive and time consuming.
For example, quantification along a major axis of a 1cm tumour using several histological sections can take up to 200 hours.
This experience prompted the UCHC team to develop a box-counting routine to interrogate digitised microscope images of well-resolved vascular networks.
A Maple program generates a binary map of the microscope images adjusted by selected thresholds.
A second algorithm creates an adjustable-size square box that peruses the entire binary image and tests each pixel site for a value (1 or 0) to provide the basis for counting intersections (1s) and non-intersecting spaces (0s).
In the small limit of s, a relative measure of the vascular density can thus be achieved in a matter of seconds.
The measurements are used to validate the MR images.
The UCHC team is demonstrating new ways that MRI can be used as a superior way to detect and characterise small (2-4mm), rapidly-growing tumours. This research will enable doctors to use non-invasive MRI to identify and characterise human cancer tumours in their early stages of development and quantitatively follow the course of therapies.
To date preliminary results have been done on mice. Clinical trials with human patients are anticipated in the near future.
Maple is supplied and supported in the UK and Ireland by Adept Scientific.
